Clinical trials
Prostate clinical trials
Below are recruiting prostate clinical trials, each written for real people, not researchers. We’re tracking 1,360 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04861415Recruiting
Testing a shorter radiation plan versus standard prostate radiation
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
Toronto, OntarioAges 18 years+ - NCT05019846RecruitingPhase 3
Radiation alone versus radiation plus hormone therapy for prostate cancer
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Brescia, BSAges 18–80 - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT05884632Recruiting
Personalized daily radiation for prostate cancer after surgery
This trial studies a “daily adaptive” way of planning and delivering radiation after prostate surgery to treat prostate cancer that is coming back locally. It may help target the tumor more precisely while limiting radiation to healthy tissue.
Negrar, VeronaAges 18–80 - NCT04654338RecruitingPhase 2/Phase 3
Two types of targeted radiation for favorable prostate cancer
This trial tests whether two “ablative” (high-dose, focused) radiation treatments can work well for men with favorable-risk prostate cancer. It looks at whether the treatments are practical and safe, especially for urinary side effects.
Toronto, OntarioAges Any age - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80 - NCT04549688Recruiting
Active surveillance with focused ultrasound for prostate cancer
This trial studies whether a high-intensity focused ultrasound treatment can help people with localized prostate cancer while still avoiding traditional full-dose treatment for some patients. It may be an option for certain intermediate-risk cases where the cancer is confined to the prostate.
Tønsberg, VestfoldAges 18–80 - NCT05832736Recruiting
Robot surgery for one-sided prostate cancer with urethra preserved
This study looks at a robotic prostate operation that aims to remove only the affected side while keeping the urethra (the tube for urination) to help preserve urinary function. It’s for people with low- to intermediate-risk, one-sided prostate cancer and no spread to lymph nodes, bones, or other organs.
Candiolo, TOAges 40 years+ - NCT05781217RecruitingPhase 3
Short vs longer hormone therapy after salvage prostate radiation
This trial compares two lengths of hormone treatment (androgen deprivation therapy) given around “salvage” radiation after prostate surgery for rising PSA. It aims to see which schedule works best to control prostate cancer while keeping side effects manageable.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT05767307Recruiting
MRI for suspected prostate cancer in Denmark
This study is enrolling adults who have prostate cancer concerns and are being sent for an MRI scan. It aims to improve evaluation of suspected prostate cancer, which may help doctors decide next steps more accurately.
Aarhus N, AarhusAges 18–99 - NCT06167629Recruiting
PSMA PET scan study for prostate cancer
This study uses a special type of PET scan called PSMA PET to better understand and track prostate cancer. The scan helps doctors see where the cancer is in the body and if treatment is working.
MilanAges 18 years+ - NCT03908684Recruiting
Ultrasound tests to predict early response to prostate and head/neck radiation
This study uses special ultrasound imaging to look for early signs of how well radiation treatment is working in prostate, rectum, and head/neck cancers. It may help doctors spot response sooner and adjust care earlier if needed.
Toronto, OntarioAges Any age - NCT04831983Recruiting
Radiation treatment for intermediate- and high-risk prostate cancer
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
Monza, MBAges 18–90 - NCT05851547RecruitingPhase 2
Testing higher doses in prostate spots using MRI guidance
This Phase 2 trial studies a way to deliver higher radiation doses to specific prostate lesions seen on a 3-Tesla MRI. It’s for people with certain intermediate- or high-risk prostate cancer to see if targeting the lesions can improve treatment results and safety.
Ottawa, OntarioAges 18 years+ - NCT07871110RecruitingPhase 2
New pill combined with hormone therapy for advanced prostate cancer
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
Fuzhou, FujianAges 18 years+ - NCT06219746Recruiting
New imaging scan for high-risk prostate cancer staging
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
Turku, Southwest FinlandAges 18 years+ - NCT06236789Recruiting
Ifosfamide for men with advanced prostate cancer
This trial is studying whether the chemotherapy drug ifosfamide (given with mesna to protect the bladder) can help men whose prostate cancer has spread and is no longer controlled by hormone therapy. It is for men who have already tried the chemotherapy docetaxel.
SeoulAges 19 years+ - NCT07871435RecruitingPhase 1/Phase 2
Investigational combo for advanced prostate cancer
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT06249750RecruitingPhase 2
Heat shock therapy for castration-resistant prostate cancer
This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.
Hangzhou, ZhejiangAges 18–90 - NCT07860047RecruitingPhase 2
Peptide vaccine with antibody therapy for prostate cancer
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
Heidelberg, Baden-WurttembergAges 18–80 - NCT04642027RecruitingPhase 3
PSMA scan-guided salvage radiation after prostate surgery
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
Arnhem, GelderlandAges 18–80 - NCT06270043Recruiting
Focal therapy study for early-stage prostate cancer
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
La Jolla, CaliforniaAges 18 years+ - NCT04612907Recruiting
Radiation timing options for low-burden metastatic prostate cancer
This study compares different radiation schedules to the main prostate tumor in men with low-burden metastatic (spread) hormone-sensitive prostate cancer. It may help find a radiation timing approach that controls the cancer while balancing side effects.
UmeåAges 18 years+ - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate?
- Yes. Clin2 currently lists 1,360 recruiting prostate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.